A company can buy a well-being program. An executive can arrange private treatment. Neither decision establishes that returning to the same working conditions will be sustainable. Great Britain’s working-days-lost figures show the scale of the problem. Treatment research asks a second question: how well do clinical care and the return to work fit together?
Key findings
22.1 million: estimated working days lost to work-related stress, depression, or anxiety in Great Britain in 2024/25.
16.4 million: the corresponding published estimate for 2023/24.
964,000: workers affected under the latest HSE survey definition.
22.9 days: average time lost per affected person in 2024/25, not a recommended recovery period.
The figures cover the relevant working population in England, Scotland, and Wales. They are not an executive-specific study or a count of diagnosed burnout. [1] [2] [3]
The annual absence comparison
Sources: HSE’s 2023/24 bulletin and 2024/25 days-lost publication. This comparison shows published estimates, not the cause or statistical significance of the annual difference. [1] [2]
What belongs in the total
The 22.1 million days sit within an estimated 35.7 million days lost to work-related ill health. A wider total of 40.1 million includes nonfatal workplace injuries. Those denominators answer different questions. A report should not change between them without explaining the difference.
| Measure | Estimated days | Scope |
|---|---|---|
| Stress, depression, or anxiety | 22.1 million | Part of work-related ill health |
| Musculoskeletal disorders | 7.1 million | Part of work-related ill health |
| All work-related ill health | 35.7 million | Includes the categories above |
| Nonfatal workplace injuries | 4.4 million | Additional to ill health |
| Ill health and nonfatal injuries | 40.1 million | Combined total |
Source: HSE. Rows overlap and must not be added together. Figures are rounded survey estimates. [1]
The same discipline matters when discussing costs. An estimate covering all workplace injury and illness cannot be relabeled the cost of burnout. A striking number becomes less useful, not more useful, when its category changes halfway through the argument.
Burnout is not a substitute for diagnosis
WHO classifies burnout as an occupational phenomenon related to chronic workplace stress, not as a medical condition. HSE’s combined stress, depression, or anxiety measure is different. Neither should be presented as a count of clinically diagnosed executive burnout. [4]
For someone seeking help, the preferred label should not settle the assessment. The useful questions concern the difficulties experienced, their impact, and other explanations or co-occurring conditions. A treatment plan should follow that assessment rather than begin with a marketing category.
For a family business, an exhaustion questionnaire, absence record, and clinical depression assessment also measure different things. They can inform a broader investigation, but are not interchangeable confirmations of the same prevalence rate.
What treatment research adds
A Cochrane review found that combining work-directed changes with clinical treatment for people with depression probably reduced sickness-absence days within the first year. Its summary translated the pooled finding to about 25 fewer days per person over a year, based on nine studies involving 1,292 participants. [5]
That estimate is not a guaranteed saving for an employer or a recovery target for a patient. The review did not show an equivalent reduction in the number of people off work for that comparison. Days absent and whether someone remains absent are different outcomes.
The finding does not mean that every workplace intervention works or that a managerial adjustment can replace clinical treatment. It supports examining the combination. The practical question is whether the care plan and the work plan address the same person’s needs.
Absence duration is not a treatment timetable
Source: HSE. These averages describe absence, not how long recovery or treatment should take. [1]
A person can return to work while still experiencing substantial difficulties. Another can improve clinically while appropriately remaining away. An attendance measure and a health measure can therefore move differently without either being wrong.
A useful outcome report would include symptoms, daily functioning, sustainable participation, and the person’s goals. It would record subsequent treatment and follow-up. Speed of return should not become the sole definition of success.
Why the executive angle needs care
The national statistics do not establish that seniority creates greater risk or describe high-net-worth individuals separately. Resources, autonomy, demands, and support vary between workers. A study of executives would need to measure those circumstances rather than infer them from a demanding title.
The practical relevance to leaders is nevertheless clear. They may be deciding both how to obtain care themselves and how others can return to work. Paying for a program addresses one part of that situation. It does not demonstrate that workload, responsibilities, or support have been examined.
For an owner-manager, stepping away may raise different practical questions from those faced by an employee. Who can provide cover? Which decisions can wait? What information can be shared appropriately? These are questions for planning, not a basis for inventing a founder-specific absence statistic.
An international family should also know who coordinates care when travel or residence changes. The relevant clinical and occupational professionals need to consider the person’s circumstances. This article does not provide an individual fitness-for-work assessment or a universal return schedule.
A return plan should answer practical questions
| Area | Question |
|---|---|
| Clinical progress | What improved, and what still needs care? |
| Role and workload | Which responsibilities can be resumed sustainably? |
| Confidentiality | What does the person agree to share, and with whom? |
| Continuity | Who coordinates follow-up across changes? |
| Evaluation | How will health, functioning, and personal goals be reviewed? |
This proposed framework distinguishes a temporary break from a supported transition. It does not assume that everyone should disclose a diagnosis at work or resume the same responsibilities. Decisions need to reflect consent, clinical advice, and the relevant circumstances.
The plan should also explain how problems will be recognized after return. A positive final appointment is not the end of the pathway. Agreeing on review points and responsibilities makes the next step clearer if the original workload proves unsustainable or symptoms require reassessment.
The financial story needs its own evidence
Multiplying lost days by an executive’s salary can produce a dramatic number without measuring the true economic effect. Pay is not a direct measure of output, colleagues may cover responsibilities, and the consequences differ between roles. A defensible estimate needs a stated perspective and transparent assumptions.
Likewise, comparing a program’s price with an assumed loss does not establish a return on investment. The analysis would need to ask what would have happened without the intervention. A before-and-after improvement alone cannot provide that comparison.
The absence of a precise financial figure does not weaken the importance of appropriate care. Clinical need and human benefit should remain visible without an invented promise of commercial payback. This is particularly important when the person seeking help also owns the business being discussed.
Keep the two decisions separate
A clinical decision asks what care the person needs. A workplace decision asks how responsibilities can be managed while that care continues. They should inform one another without becoming the same decision. A business preference for an immediate return is not a clinical outcome measure, just as an absence statistic cannot determine an individual’s fitness for a particular role.
For families and owner-managers, separating those questions can make the discussion clearer. It allows practical cover, confidentiality, treatment, and later review to be considered explicitly. The objective is not simply to record that someone returned, but to understand whether the arrangement remains sustainable when ordinary demands resume.
What the numbers cannot tell us
The HSE figures cover Great Britain, not the entire UK, and use self-reported work-related categories. They do not establish executive prevalence, individual recovery time, or the cause of the annual change. The treatment review concerns selected interventions and patients with depression, not every well-being initiative.
No workforce microdata, company accounts, or THE BALANCE patient records were analyzed. The charts preserve reported estimates and do not add confidence intervals that were not established for this comparison.
The bottom line
The 22.1 million-day figure makes work-related mental health difficult to dismiss. The more useful question comes afterward: what changes when someone returns? An accountable treatment pathway should address that transition without promising a universal timetable or guaranteed business return.
For journalists
Key comparison: 22.1 million estimated days lost in 2024/25 versus 16.4 million in 2023/24.
Important caveat: work-related stress, depression, or anxiety is not the same measure as diagnosed burnout.
Suggested attribution: THE BALANCE analysis of HSE absence statistics and published return-to-work evidence.
Methodology and sources
This narrative analysis compares published HSE estimates and selected treatment evidence. Overlapping totals remain separate. The Cochrane result is not converted into a company saving, and no causal effect of job seniority, wealth, or private treatment is estimated.
